Using adeno‐associated virus vectors which disrupt mutated COL1A2 genes in OI mesenchymal stem cells has resulted in normal type I procollagen and bone generation, which may be another promising therapeutic technology for OI (Chamberlain et al., 2008). This evidence concerns the gene COL1A2 and osteogenesis imperfecta.